Eluvia™ Drug | 合法醫療器材資訊網

Eluviaprovidesconsistent,durableoutcomesinchallengingSFAdiseaseandfeaturesapolymer...oftreatingtheSFAandhowdrug-elutingvascuarstentsmayhelpimprovepatientoutcomes....Indications,Safety,andWarnings...Products;Products·Cu

In the world’s first head-to-head DES SFA trial1, Eluvia demonstrated the highest ever reported 2-year Kaplan-Meier primary Patency of 83%2 and showed low 2-year TLR in patients with long lesions, diabetes, CTOs, and severe/moderate calcium. 

As the only device using polymer to elute drug for PAD, Eluvia features the lowest drug dose with the fewest downstream particulates3, leaving no paclitaxel in the bloodstream at 30 minutes post implant.4[1]

Available now in 150mm length. Ask your sales representative about Eluvia 150.